Coggins showed that the MEK inhibitor trametinib induces YAP nuclear translocation while reducing cytoplasmic YAP in RAS- or NF1-mutated neuroblastoma cell lines, suggesting resistance to MEK inhibitor therapy via YAP activation [52]. The gene discussed is NF1; the disease is neuroblastoma.